An Aim-listed company that tests infectious and respiratory disease products on volunteers is preparing to move its operations to Canary Wharf.
Amid booming demand for its services, hVIVO, which infects volunteers with safe doses of virus agents, then quarantines them before testing the efficacy of vaccines and antivirals – in so-called human challenge trials – will move from its clinics in Whitechapel, east London, to a new larger facility near by owned by Canary Wharf Group early next year.
Canary Wharf is aiming to attract businesses from the life sciences and health sectors in a drive to become a sciences hub and less reliant on the financial services industry.
The new facility at the Thameside business district spans two floors and comprises laboratories, an outpatient
© Times Media Limited 2023.